ZA975470B - Insulin preparations containing naci. - Google Patents

Insulin preparations containing naci.

Info

Publication number
ZA975470B
ZA975470B ZA9705470A ZA975470A ZA975470B ZA 975470 B ZA975470 B ZA 975470B ZA 9705470 A ZA9705470 A ZA 9705470A ZA 975470 A ZA975470 A ZA 975470A ZA 975470 B ZA975470 B ZA 975470B
Authority
ZA
South Africa
Prior art keywords
insulin preparations
preparations containing
containing naci
insulin
naci
Prior art date
Application number
ZA9705470A
Other languages
English (en)
Inventor
Elsebeth Norup
Liselotte Langkjaer
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA975470(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA975470B publication Critical patent/ZA975470B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9705470A 1996-06-20 1997-06-20 Insulin preparations containing naci. ZA975470B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20

Publications (1)

Publication Number Publication Date
ZA975470B true ZA975470B (en) 1997-12-22

Family

ID=8096378

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705470A ZA975470B (en) 1996-06-20 1997-06-20 Insulin preparations containing naci.

Country Status (21)

Country Link
EP (1) EP0921812B2 (pt)
JP (2) JP4404380B2 (pt)
KR (1) KR100451778B1 (pt)
CN (1) CN1120019C (pt)
AT (1) ATE208208T1 (pt)
AU (1) AU720484B2 (pt)
BR (1) BR9709845B1 (pt)
CA (1) CA2258097C (pt)
CZ (1) CZ297937B6 (pt)
DE (1) DE69708121T3 (pt)
DK (1) DK0921812T4 (pt)
ES (1) ES2167751T5 (pt)
HU (1) HU228094B1 (pt)
IL (2) IL127366A0 (pt)
NO (1) NO324430B1 (pt)
PL (1) PL189964B1 (pt)
PT (1) PT921812E (pt)
RU (1) RU2182015C2 (pt)
UA (1) UA49890C2 (pt)
WO (1) WO1997048414A1 (pt)
ZA (1) ZA975470B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
EP1131089B1 (en) * 1998-11-18 2004-02-18 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
AU2624400A (en) * 1999-01-26 2000-08-07 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
WO2000059499A1 (en) * 1999-04-05 2000-10-12 Verteletsky, Pavel Vasilievich Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
IL150129A0 (en) * 1999-12-16 2002-12-01 Lilly Co Eli Polypeptide compositions with improved stability
SI2918286T1 (sl) 2004-10-05 2020-06-30 Novo Nordisk A/S Farmacevtski pripravek, ki vsebuje inzulin v kristalni obliki in tudi v obliki raztopine
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
ES2667069T3 (es) 2009-11-13 2018-05-09 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
DK2611458T3 (da) 2010-08-30 2017-01-02 Sanofi Aventis Deutschland Anvendelse af ave0010 til fremstilling af et medikament til behandling af diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
RU2015130613A (ru) 2012-12-26 2017-01-31 Вокхардт Лимитед Фармацевтическая композиция
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CN111658604A (zh) 2014-01-09 2020-09-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
WO2015104310A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
SG11201704678SA (en) 2014-12-12 2017-07-28 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
WO1995000550A1 (en) * 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
CA2171424C (en) * 1993-09-17 2002-06-04 Svend Havelund Acylated insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
CN1120019C (zh) 2003-09-03
WO1997048414A1 (en) 1997-12-24
NO324430B1 (no) 2007-10-15
DE69708121T2 (de) 2002-08-01
CZ395698A3 (cs) 1999-05-12
ES2167751T3 (es) 2002-05-16
NO985981D0 (no) 1998-12-18
EP0921812B2 (en) 2011-12-21
HUP9904031A2 (hu) 2000-04-28
PT921812E (pt) 2002-04-29
RU2182015C2 (ru) 2002-05-10
DK0921812T3 (da) 2002-02-11
CN1222083A (zh) 1999-07-07
DE69708121D1 (de) 2001-12-13
HU228094B1 (en) 2012-10-29
IL127366A0 (en) 1999-10-28
PL330763A1 (en) 1999-05-24
AU720484B2 (en) 2000-06-01
HUP9904031A3 (en) 2000-10-30
BR9709845A (pt) 1999-08-10
NO985981L (no) 1998-12-18
KR20000022031A (ko) 2000-04-25
JP4404380B2 (ja) 2010-01-27
IL127366A (en) 2007-07-04
EP0921812B1 (en) 2001-11-07
AU3253697A (en) 1998-01-07
KR100451778B1 (ko) 2004-11-16
BR9709845B1 (pt) 2008-11-18
UA49890C2 (uk) 2002-10-15
CZ297937B6 (cs) 2007-05-02
CA2258097C (en) 2011-02-08
ATE208208T1 (de) 2001-11-15
DE69708121T3 (de) 2012-05-16
DK0921812T4 (da) 2012-04-02
EP0921812A1 (en) 1999-06-16
CA2258097A1 (en) 1997-12-24
JP2000513344A (ja) 2000-10-10
PL189964B1 (pl) 2005-10-31
JP2009235075A (ja) 2009-10-15
ES2167751T5 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
ZA975470B (en) Insulin preparations containing naci.
AU635358B2 (en) Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
ATE369146T1 (de) Insulinpreparation mit mannitol
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ZA200102105B (en) Stable concentrated insulin preparations for pulmonary.
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
NO20012249L (no) Faststoffsammensetning inneholdende D-mannitol og cerivastatin samt anvendelse av faststoffsammensetning forfremstilling av farmasöytisk preparat
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
AU7340091A (en) Fire extinguishing methods and compositions utilizing 2-chloro-1,1,1,2-tetrafluoroethane
AU631334B2 (en) 2-substituted n,n'-ditrimethoxybenzoyl piperazines, and therapeutic compositions containing them
ATE196914T1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
AU581956B2 (en) 6-chloro-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine- N-oxide and medical compositions using it
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
FI954401A (fi) Atseotrooppimaiset koostumukset, joissa on 1,1,1,2,3,3,3-heptafluoripropaania ja 1,1-difluorietaania
ATE70840T1 (de) Benzothiepino(5,4-c>pyridazin-verbindungen und ihre pharmazeutischen wirkungen.